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ABSTRACT
Background: Acute renal failure (ARF) is a possible com-
plication after percutaneous coronary intervention (PCI). 
The objective of this study was to evaluate the occurrence 
and prognostic impact of ARF after PCI in patients with ST 
segment elevation myocardial infarction (STEMI). Methods: 
Single-center registry evaluating in-hospital outcomes of 501 
patients admitted with STEMI undergoing primary, rescue 
or late PCI. The incidence and predictors of ARF after PCI 
were evaluated. Results: Mean age was 60.7 ± 12.6 years 
and 67% were male. The populaton had high cardiovascular 
risk characteristics, with 30% of diabetics and 7.4% with 
preexisting chronic kidney disease (CKD). The left anterior 
descending artery was the culprit vessel in 49.4% of the 
cases and 15% of patients had Killip class III or IV. ARF 
was observed in 24.7% of patients, who were significantly 
older, had more diabetes, history of CKD or heart failure, 
had higher enzyme elevation and lower ejection fraction 
when compared to those without ARF. In-hospital mortality 
was higher in patients who developed ARF (29% vs. 4.8%; 
P < 0.01). Independent predictors of ARF were age > 76 
years, previous CKD, Killip class III or IV, need of vascular 
surgery or blood transfusion. Conclusions: Acute renal failure 
after PCI in STEMI was a frequent complication and was 
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RESUMO
Impacto da Insuficiência Renal Aguda na Evolução 
Hospitalar Após Tratamento Percutâneo do Infarto 
Agudo do Miocárdio
Introdução: A insuficiência renal aguda (IRA) é uma complicação 
possível após intervenção coronária percutânea (ICP). O objetivo 
deste estudo foi avaliar a ocorrência e o impacto prognóstico 
da IRA pós-ICP em pacientes com infarto agudo do miocárdio 
com supradesnivelamento do segmento ST (IMCSST). Métodos: 
Registro unicêntrico, que analisou a evolução hospitalar de 501 
pacientes admitidos com IMCSST submetidos à ICP primária, de 
resgate ou tardia. Foram avaliados a incidência e os preditores 
de IRA pós-ICP. Resultados: A idade média foi 60,7 ± 12,6 anos 
e 67% eram do gênero masculino. A população apresentava 
características de alto risco cardiovascular, sendo 30% diabéticos 
e 7,4% com doença renal crônica (DRC) preexistente. A artéria 
descendente anterior foi a principal artéria culpada (49,4%) e 15% 
dos pacientes se apresentaram em Killip III ou IV. A IRA ocorreu 
em 24,7% dos pacientes, que, quando comparados àqueles sem 
IRA, eram significativamente mais idosos, diabéticos, com DRC 
e insuficiência cardíaca, além de apresentarem maior elevação 
enzimática e menor fração de ejeção. A mortalidade hospitalar 
foi maior nos pacientes que desenvolveram IRA (29% vs. 4,8%; 
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associated with increased in-hospital mortality.
 
 
DESCRIPTORS: Renal insufficiency. Percutaneous coronary 
intervention. Myocardial infarction.
a history of chronic renal disease, were analyzed.
Procedures
In all procedures, unfractionated heparin at a dose 
of 70 to 100 U/kg was previously administered, so that 
an activated clotting time between 250 and 300 seconds 
was obtained, except for those who were already us-
ing low molecular weight or unfractionated heparin at 
the admission to Hemodynamics, when the dose was 
adjusted according to the half-life of the drug used or 
to the results of the activated clotting time. The patients 
received dual antiplatelet therapy with acetylsalicylic acid 
and clopidogrel. During the diagnostic and therapeutic 
procedures, care was taken to minimize the volume of 
contrast and avoid drugs with nephrotoxic potential. At 
the discretion of the physician and according to the 
clinical condition, the patients received periprocedural 
saline hydration.
The choice of the route, techniques, materials, and 
diagnostic and interventional methods was left at the 
surgeon’s discretion. All angiograms were analyzed by 
the Department of Interventional Cardiology, InCor/
HCFMUSP. Image acquisition was performed using two 
or more angiographic projections of the stenosis after 
administration of vasodilators.
Definitions
The diagnosis of STEMI was conducted in light of 
the occurrence of a persistent ST elevation > 1 mm in 
two contiguous leads, or of a new left bundle branch 
block on the electrocardiogram in patients with a clini-
cal picture suggestive of myocardial ischemia. 
ARF was defined as a 25% baseline increase in 
serum creatinine or an absolute increase of 0.5 mg/
dL in serum creatinine assessed in the first seven days 
after the completion of the procedure.10 Initial tests 
of creatinine were obtained from previous values in 
patient’s medical record or from tests collected in the 
emergency room, at hospital admission.
PCI was defined as a primary procedure when it 
was performed in the acute phase of AMI (< 12 hours or 
between 12 and 24 hours in the presence of symptoms) 
P < 0,01). Os preditores independentes de IRA foram idade > 
76 anos, DRC prévia, Killip III ou IV, necessidade de cirurgia 
vascular ou transfusão sanguínea. Conclusões: A disfunção renal 
aguda após ICP no IMCSST foi uma complicação frequente e 
associada com aumento da mortalidade hospitalar.
DESCRITORES: Insuficiência renal. Intervenção coronária 
percutânea. Infarto do miocárdio.
C oronary artery disease is a major cause of mor-tality in developed countries. Although mortality after acute myocardial infarction (AMI) have been 
reduced in recent decades, there are still subgroups of 
patients who are at higher risk of complications and 
death, such as those with kidney dysfunction.1-3
Patients undergoing percutaneous coronary interven-
tion (PCI) after AMI represent a population at high risk 
for developing acute renal failure (ARF), since many 
conditions can favor its occurrence, such as hypoten-
sion, ventricular dysfunction, the use of drugs with 
nephrotoxic potential, and inability to start prophylactic 
measures in the context of the emergency. Some trials 
have demonstrated that renal dysfunction is an inde-
pendent predictor of risk of death in AMI.4-6 PCI also 
has the potential to cause renal dysfunction induced 
by the use of contrast medium. Its occurrence in diag-
nostic and therapeutic examinations has been related 
to an increase in in-hospital morbidity and mortality, 
prolonged hospital stay, development of chronic renal 
failure, and dialysis.7-9
The aim of this trial was to evaluate the impact of 
ARF on in-hospital outcomes of patients with AMI with 
ST-segment elevation (STEMI) treated percutaneously.
METHODS
Study population
STEMI patients undergoing primary, rescue, or 
late PCI were evaluated in a single center, Instituto do 
Coração, Hospital das Clinicas, School of Medicine, 
Universidade de São Paulo (InCor/HCFMUSP), São Paulo, 
Brazil, from January 2008 to March 2011.
Data collection 
Data from in-hospital evolution were prospectively 
collected during the index hospitalization, following 
the completion of previously standardized forms; all 
patients signed an informed consent to participate 
in a PCI study. The data collection included clinical 
characteristics, laboratory test results, and data from the 
invasive procedure and clinical outcome until hospital 
discharge. Patients who developed ARF, with or without 
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using balloon catheter or stent, without previous use of 
fibrinolytics, aiming to restore the antegrade coronary 
flow. Rescue PCI was considered as the procedure per-
formed when the fibrinolytic agent was not successful 
in reperfusion of the ischemic muscle (resolution of ST 
elevation <  50% in the first 60 minutes of administra-
tion). The clinical picture was defined as a late PCI 
when the procedure was performed > 24 hours after 
the onset of symptoms.
Death was defined as death from any cause. The 
vascular complications evaluated were pseudoaneurysm, 
arteriovenous fistula, significant hematoma at the access 
site (defined by a diameter ≥ 10 cm), and significant 
bleeding (defined as a fall in hemoglobin > 2 g/dL or 
which required blood transfusion).
Statistical analysis
Continuous variables were described as mean ± 
standard deviation and compared using the Wilcoxon 
test. Categorical variables were represented as percent-
ages and compared with chi-squared test. The clinical 
and angiographic characteristics presented were included 
in a regression model to detect predictors of ARF fol-
lowing the procedure.
All tests were two-tailed and a P value < 0.05 was 
considered significant. The analyses were performed using 
the Statistical Package for the Social Sciences (SPSS) soft-
ware, version 17.0 (SPSS Inc., Chicago, Estados Unidos).
RESULTS
From January 2008 to March 2011, 501 patients 
consecutively admitted with STEMI were evaluated, 
and their clinical characteristics were summarized in 
Table 1. The patients were predominantly male (67%) 
with a mean age of 60.7 ± 12.6 years; 29.7% were 
diabetic. Chronic renal disease was observed in 7.4% 
of the trial population. Regarding the type of proce-
dure, primary PCI was performed in 59.2%, rescue PCI 
in 15.3%, and late PCI in 25.5% of cases. The time 
elapsed between the onset of symptoms and hospital 
admission (pain-to-door time) was 5 hours and 12 
minutes, with no statistical difference between patients 
who developed ARF and those who preserved normal 
renal function (P = 0.27). The left anterior descending 
artery was the location most related to the infarction 
(49.4%), followed by the right coronary (39.8%) and 
left circumflex artery (10.8%). Regarding the hemody-
namic presentation at hospital admission, most patients 
were in Killip class I (75%), however, about 15% of 
the patients had already been presented in Killip class 
III or IV. Glycoprotein IIb/IIIa inhibitors were used in 
approximately one-third of cases.
ARF after PCI occurred in 124 (24.7%) patients. 
Comparatively, patients who developed ARF were older, 
diabetic, and more often had a history of chronic renal 
disease and heart failure. In this group, a lower left 
ventricle ejection fraction (40.2% vs. 47%; P  <  0.01) 
was also observed, and a greater increase in cardiac 
enzymes (peak CK-MB: 255.8 IU/L vs. 213.3 IU/L; P = 
0.01). There was no difference between the two groups 
with regard to time of onset of symptoms and hospital 
admission (pain-to-door time) or the type of PCI (pri-
mary, rescue, or late) performed, as shown in Table 1.
In relation to in-hospital outcomes, it was observed 
that patients with ARF had significantly higher mortality 
than patients without loss of renal function (29% vs. 
4.8%; P  <  0.01). Among the deaths, 87.3% occurred 
from cardiovascular causes and 34% of patients had 
infectious complications that contributed to the outcome. 
It was also observed that patients with ARF had a greater 
need for transfusions, without significant increase in the 
incidence of fistulas, pseudoaneurysms, or bleeding at 
the access site (Table 2). There was also a tendency, 
although not statistically significant, for a higher inci-
dence of hemorrhagic stroke (1.6% vs. 0%; P = 0.06). 
Among patients who developed ARF, approximately 
12% required dialysis during the in-hospital period.
The following factors were identified as independent 
predictors of occurrence of ARF during the in-hospital 
period: age > 76 years, history of chronic renal dis-
ease, Killip class III or IV at initial presentation, and 
vascular surgery or need for blood transfusion (Table 
3). Patients presenting preserved left ventricular systolic 
function with an ejection fraction > 60% had a lower 
occurrence of ARF.
DISCUSSION
ARF is a possible complication after coronary 
diagnostic or therapeutic procedures, and its develop-
ment has been associated with prolonged hospital stay, 
persistent renal dysfunction, and early and late mortal-
ity. Observational clinical trials have demonstrated that 
renal dysfunction is an independent risk factor for death 
in patients with AMI.4-6,11 In the GRACE registry, an 
increase of 1 mg/dL in the initial creatinine increased 
the risk for in-hospital death by 20%.12
The present study observed that ARF is a frequent 
complication after PCI in patients hospitalized with 
STEMI, occurring in almost one-quarter of patients. 
Sadeghi et al.6 and Lanza et al.13 found ARF in 18% 
and 15.3% post-AMI patients, respectively. In the pres-
ent study, it was observed that the main independent 
predictors of occurrence of ARF were age > 76 years, 
history of chronic renal disease, Killip class III or IV 
at hemodynamic presentation, and a need to perform 
vascular surgery or blood transfusions. The presence 
of an ejection fraction > 60% was an independent 
protective factor for ARF. Marenzi et al.14 studied 208 
patients with AMI and observed a post-PCI incidence 
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Without ARF  
(n = 377) P value
Male,% 67.8 67.9 67.8 0.90
Age, years 60.7 ± 12.6 65.6 ± 12.9 59.1 ± 12.1 < 0.01
Diabetes, % 29.7 38.7 26.8 0.03
Hypertension, % 75.5 81.5 73.5 0.17
Dyslipidemia, % 70.3 72.6 69.8 0.25
Current smoking, % 42.6 35.5 44.8 0.09
FH of early CAD, % 29.5 21.8 32.1 0.07
Prior CRF, % 7.4 20.2 3.2 < 0.01
Prior renal transplantation, % 0.8 0.8 0.8 > 0.99
PAD, % 7 12.1 5.3 0.03
Heart failure, % 12.4 21 9.5 < 0.01
Prior PCI, % 13.9 12.1 14.6 0.72
Previous CABG, % 5.8 9.7 4.5 0.09
Killip < 0.01
I 75.2 45.5 85.1
II 9 12.2 8
III 3.8 10.6 1.6
IV 12 31.7 5.3
Pain-to-door time, minutes 312 ± 272 349 ± 288 301 ± 249 0.27
Target artery, % 0.07
LAD 49.4 54.0 47.8
RCA 39.8 39.5 40.0
LCx 10.8 6.5 12.2
LVEF, % 45.7 ± 11.6 40.2 ± 10.7 47.6 ± 11.3 < 0.01
PCI type, % 0.40
Primary 59.2 61.3 58.3
Rescue 15.3 15.3 15.4
Late 25.5 23.4 26.3
Use of GP IIb/IIIa% 33.1 30.6 33.9 0.50
ARF = acute renal failure; FH CAD = family history of coronary artery disease; CRF = chronic renal failure; PAD = peripheral arterial 
disease; PCI = percutaneous coronary intervention; CABG = coronary artery bypass grafting; LAD = Left anterior descending artery; RCA 
= right coronary artery; LCx = left circumflex artery; LVEF = left ventricular ejection fraction; GP = glycoprotein.
TABLE 2 






Without ARF  
(n = 377) P value
Mortality,% 10.8 29 4.8 < 0.01
Ischemic stroke,% 0.8 1.6 0.5 0.25
Hemorrhagic stroke,% 0.4 1.6 0 0.06
Pseudoaneurysm,% 1.6 1.6 1.6 > 0.99
AV fistula,% 0.2 0.8 0 0.24
Vascular surgery,% 1.7 4.0 1.1 0.03
Bleeding by access route, % 3.7 5.6 3.1 0.16
Transfusion,% 2.8 8.1 1.1 < 0.01
AV = arteriovenous.
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of ARF of 19%, reporting a high risk among older 
patients with renal dysfunction at hospital admission 
and greater enzymatic elevation – findings similar to 
those observed in the present study.They also observed 
an increased risk for patients with lower left ventricle 
ejection fraction, greater delay for myocardial reperfu-
sion, and for patients with anterior wall AMI, possibly 
related to the higher contrast volume reported by the 
investigator to treat this territory and/or by a greater 
hemodynamic compromise.
Worsening of renal function has been associated 
with an increased risk of bleeding and of vascular 
access-related complications after PCI.15 Some trials sug-
gest a relationship between the occurrence of bleeding 
and increased mortality in patients with AMI.16,17 In the 
context of primary PCI, in which there is a particularly 
high risk due to the need for aggressive anticoagula-
tion and antiplatelet therapy, the incidence of vascular 
complications in this subgroup of patients with renal 
dysfunction remains uncertain.18 In the present study, no 
significant increase in complications related to arterial 
access (pseudoaneurysms, fistulas, or significant bleed-
ing at the access site) was observed in patients with 
impaired renal function after coronary intervention: 8.0% 
in patients with ARF and 4.7% in those without renal 
dysfunction. However, the need for blood transfusion 
due to bleeding of other origin was an independent 
predictor of renal failure in these patients (OR = 4.51, 
95% CI 1.01-20.16; P = 0.05).
In this study, in-hospital mortality was significantly 
higher in patients who developed loss of renal function 
after PCI (29% vs. 4.8%; P <  0.01). Similarly, several 
authors have found a significant increase in early and 
late mortality in patients with post-PCI loss of renal 
function in AMI.6,11,14,19 Rihal et al.,9 defining ARF as an 
increase in creatinine ≥ 0.5 mg/dL, observed that patients 
with renal dysfunction had an in-hospital mortality of 
22%, compared with 1.4% in those with normal renal 
function. Sadeghi et al.6 demonstrated that patients with 
renal dysfunction at any time during the hospital stay 
after primary PCI had a significant increase in 30-day 
mortality (RR = 13.8; 95% CI 7.3-26.2) and at one year 
(RR = 7.4; 95% CI 4.7-11.7). Some authors argue that 
this increased mortality persists even after a long period 
of observation. Amin et al.20 reported that the worsening 
of renal function was associated with a higher risk of 
death in patients with AMI, even after 4 years (HR = 
1.64; 95% CI 1.23-2.19). An increased mortality was also 
observed in patients with previous chronic renal failure 
to the procedure. Gruberget al.21 reported that patients 
who had an increase of 25% in baseline creatinine had 
an in-hospital mortality of 14.9%, compared with 4.9% 
for those without additional renal dysfunction.
Brown et al.11 demonstrated that both transient and 
persistent changes in renal function are associated with 
a worse prognosis in short and long term. Some trials 
have shown that up to 45 to 50% of patients who 
develop renal dysfunction may be unable to return to 
normal renal function after between two and four weeks 
of evolution.11,22 Wi et al.22 showed that patients with 
transient renal dysfunction after PCI in an AMI scenario 
presented, in two years, lower risk of death or dialysis 
compared to those with persistent renal dysfunction 
(17.9% vs. 34.1%; P = 0.013). However, even those 
with transient renal dysfunction had a higher rate of 
events compared with those without renal dysfunction 
(17.9% vs. 6.3%; P <  0.001).
Some trials have suggested that patients with renal 
disease are less likely to receive pharmacological ther-
apies or to undergo CABG when compared to those 
with preserved renal function.23,24 In addition, patients 
with deterioration of their renal function presented a 
higher number of risk factors compared to the group 
of patients who maintained normal renal function, such 
as advanced age, diabetes, and previous chronic heart 
failure.20 Lazaros et al.19 also observed that patients in 
whom renal function deteriorated during the in-hospital 
period showed a more important and less completely 
treated coronary artery disease, with greater degree of 
myocardial necrosis and of neurohormonal activation 
– factors that may contribute to a worse outcome in 
these patients.
Mehran et al.25 developed a scoring system to as-
sess the risk of ARF after PCI, including clinical and 
procedural variables: hypotension, intra-aortic balloon, 
congestive heart failure, chronic renal disease, diabetes, 
age > 75 years, anemia, and volume of contrast. In an 
AMI scenario, Wi et al.26 showed that the Mehran risk 
score was a significant independent predictor of persis-
tent renal dysfunction and of late adverse cardio and 
cerebrovascular events in patients who underwent PCI.
TABLE 3 
Independent predictors of acute  
renal failure (n = 501)
Predictors
Odds 
Ratio 95% CI P value
Age > 76 years 2.54 1.44-4.50 < 0.01
CRD 6.47 2.45-17.09 < 0.01
LVEF > 60% 0.95 0.93-0.98 < 0.01
Killip III 7.07 1.87-26.69 < 0.01
Killip IV 6.53 3.20-13.33 < 0.01
Blood transfusion 4.51 1.01-20.16 0.05
Vascular surgery 7.45 1.61-34.54 0.01
CRD = chronic renal disease; LVEF = left ventricle ejection 
fraction.
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If the patient has risk factors, some authors sug-
gest the adoption of preventive measures against the 
development of renal dysfunction.27 One of the most 
importantis proper hydration. The most effective protocol 
has not been well defined yet, but one trial showed that 
an infusion of isotonic saline at the rate of 1 mL/kg/h 
for 48 hours was associated with a significant reduction 
in the incidence of renal failure (3.7%) compared to 
unrestricted oral rehydration (34%).27 N-acetylcysteine , 
although representing an inexpensive pharmacological 
intervention and virtually without side effects, had its 
indication challenged after the negative results of the 
ACT trial,28 and is no longer routinely recommended 
for prevention of nephropathy after percutaneous pro-
cedures. Nephrotoxic drugs also increase the risk of 
nephropathy; the recommendation is for their discon-
tinuation at least 24 hours prior to procedure , when 
possible. Furthermore, the use of a smaller amount of 
low- or iso-osmolar contrast is associated with a lower 
incidence of renal complications.29
Study limitations
This non-randomized, observational study was 
conducted at a single referral center in this institution’s 
cardiology service. Furthermore, the trial presented 
limitations in the evaluation of ischemia time, because 
it was not possible to measure the door-to-balloon time 
– an important variable, due to its association with 
mortality. Additionally, the calculation of cre atinine 
clearance was not performed, because it was not pos-
sible to obtain information regarding the amount of 
contrast used and the dosage of potentially nephro toxic 
medications – known predictors of ARF after procedures 
using iodinated contrast.
CONCLUSIONS
The occurrence of acute renal failure after percu-
taneous coronary intervention in patients with acute 
myocardial infarction with ST segment elevation is 
a frequent complication, and is associated with in-
creased mortality in this group of patients. Advanced 
age, the presence of chronic renal disease prior to 
the procedure, a clinical presentation in Killip class 
III or IV, and the need for vascular surgery or blood 
transfusion were the main independent predictors 
of acute renal failure in this study. Monitoring renal 
function in acute myocardial infarction may contribute 
significantly to the risk stratification and treatment of 
these patients.
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